Document:

exv10w60

 

Exhibit 10.60

CONFIDENTIAL
TREATMENT REQUESTED

SUBLEASE AGREEMENT

     THIS
SUBLEASE AGREEMENT (this “Sublease”), dated November 13, 2006 (the “Effective Date”),
is between BIO-RAD LABORATORIES, INC., a Delaware corporation with offices at 1000 Alfred Nobel
Drive, Hercules, California 94547 (“BIO-RAD” or "Sublessee”) and CIPIERGEN
BIOSYSTEMS, INC., a Delaware corporation with offices at 6611 Dumbarton Circle, Fremont,
California 94555 (“CIPHERGEN” or "Sublessor”). In consideration of
good and valuable consideration, including the payment to CIPHERGEN as set forth in Paragraph 3
hereof, the adequacy of which is hereby acknowledged, the parties agree as follows:

     1. Sublease of Premises.

          Subject to the consent of John Arrillaga, Trustee or his Successor Trustee, UTA dated July 20,
1977, as amended, and Richard T. Peery, Trustee or his Successor Trustee, UTA dated July 20, 1977
(the “Master Lessor”), as amended, and on and subject to the terms and conditions of that
certain Lease Agreement, dated January 28, 2000, as amended by Amendment No. 1, dated August 8,
2000 (the “Master Lease”) between CIPHERGEN and Master Lessor and the terms and conditions
set forth below, CIPHERGEN hereby subleases to BIO-RAD, and BIO-RAD hereby subleases from
CIPHERGEN, for the rent and on and subject to all of the conditions set forth herein, a portion of
that certain 60,720 ± square foot, one-story building located at 6611 Dumbarton Circle, Fremont,
California 94555 (the “Building” or the “Premises”), consisting of approximately
29,000 square feet of space as delineated on the facility map attached hereto as Schedule A (the
“Sublet Premises”). Subject to the terms and conditions of this Sublease and the Master
Lease, for so long as BIO-RAD performs its obligations under this Sublease, CIPHERGEN grants
BIO-RAD quiet possession of the Sublet Premises subject to this Sublease. To the extent such areas
are a part of the Premises leased by CIPHERGEN under the Master Lease, the term “Sublet Premises”
as used herein includes the nonexclusive use of (a) interior common areas of the Building,
including the restrooms and break room, (b) landscaped areas, sidewalks and driveways in front of
or adjacent to the Building, (c) the area directly underneath or over such sidewalks and driveways,
and (d) a pro-rata share (based on square footage) of the parking provided by the Master Lease.

     2. Term of Sublease.

          2.1 Term. This
Sublease shall become effective on November 13, 2006 (the
“Commencement Date”) and shall expire on July 31, 2008 unless terminated earlier in
accordance with the terms and conditions of this Agreement or pursuant to the Master Lease (the
“Term").

          2.2 Termination. At any time during the term, this Sublease may be terminated upon
six (6) months written notice from BIO-RAD to CIPHERGEN.

 

 

          2.3 Default. In the event BIO-RAD is in material default of any of its obligations
hereunder and fails to cure such default within thirty (30) days after written notice thereof from
CIPHERGEN (or such additional period of time as is reasonably required to cure such material
breach so long as the cure is commenced within such thirty (30) day period and thereafter
diligently pursued to completion), CIPHERGEN shall have the right to exercise any or all of the
remedies available to the Master Lessor pursuant to the Master Lease.

     3. Rent.

          3.1 Basic Rent. BIO-RAD shall pay monthly rent (“Basic Rent”) to Master
Lessor for the account of CIPHERGEN or, if not acceptable to the Master Lessor, to CIPHERGEN
during the Term, as follows:

               (a) From the Commencement Date through and including July 1, 2007, the total sum of
$1,149,830.46, payable in equal monthly installments of $127,758.94 with the exception of
the first month’s payment, which shall be prorated to cover the remaining portion of the
month following the Commencement Date;

               (b) From August 1, 2007 through and including September 1, 2007, the total sum of $258,405.67
payable in equal monthly installments of $129,202.83; and

               (c) From October 1, 2007 through and including July 1, 2008, the total sum of
$1,321,150.59, payable in equal monthly installments of $132,115.06.

In the event that the CIPHERGEN transfers any of BIO-RAD’s prepaid rental or other monetary
consideration to Master Lessor, Tenant agrees that it will identify such payment(s) to
Master Lessor in writing as a prepayment received from BIO-RAD to be applied to a future
amount owed by BIO-RAD under the Sublease.

          3.2 INTENTIONALLY OMITTED.

          3.3 Payment. Upon execution of this Sublease, B10-RAD shall pay Master Lessor for the
account of CIPHERGEN, or, if not acceptable to the Master Lessor to CIPHERGEN, the Basic Rent for
the first and last month of the Term hereunder, with the first month prorated to cover the
remaining portion of the month following the Commencement Date. Thereafter, BIO-RAD shall pay Basic
Rent in advance on or before the first day of each month during the Term and shall be considered
late if not paid by the fifth (5th) day of the month for which Basic Rent is due. All Basic Rent
payments due hereunder shall be in the form of a check or wire transfer, made payable to Master
Lessor at the address for payment of rent under the Master Lease or to CIPHERGEN (to the attention
of CIPHERGEN’s Corporate Controller at CIPHERGEN’s address set forth above) or by wire transfer to
CIPHERGEN’s account as set forth on Schedule C hereto. Basic Rent and any estimated amount of
Additional Rent shall be due on or before the first day of each calendar month. CIPHERGEN may
impose a late payment charge of five percent (5%) for any other sum payable under this Sublease
which is not paid more than ten (10) past written notice from CIPHERGEN of past due amount, BIO-RAD
shall pay any such undisputed late charges upon demand.

2

 

          3.4 Additional Rent. In addition to Basic Rent, BIO-RAD shall also pay Master
Lessor for the account of CIPHERGEN, or, if not acceptable to the Master Lessor to CIPHERGEN, a
proportionate share of the following expenses ("Additional Rent”), in
accordance with the Master Lease, allocated to the Sublet Premises by square footage of the
Sublet Premises as compared to the total Premises subject to the Master Lease, relative rates
of consumption or other equitable grounds for allocation as mutually agreed to by BIO-RAD and
CIPHERGEN:

               (a) Real property taxes;

               (b) Monthly dues payable to the Ardenwood Property Owners’ Association;

               (c) Expenses of operation, management, maintenance and repair of the common areas of the
parcel in which the Building is located including, but not limited to, license, permit and
inspection fees; security; utility charges associated with exterior landscaping and lighting
(including water and sewer charges); all charges incurred in the maintenance and replacement of
landscaped. areas, lakes, parking lots and paved areas (including repairs, replacement, resealing
and restriping), sidewalks, driveways, maintenance, repair and replacement of all fixtures and
electrical, mechanical and plumbing systems; supplies, materials, equipment and tools; the cost of
capital expenditures which have the effect of reducing operating expenses, in accordance with the
Master Lease;

               (d) The cost of insurance maintained by Master Lessor to cover loss or damage to the Building
and the parcel in which the Building is located and any increases thereto resulting from BIO-RAD’s
use of the Sublet Premises;

               (e) the cost of operation (including common utilities), management, maintenance and repair
of the Building (including structural and common areas such as lobbies, restrooms, janitor’s
closets, hallways, elevators, mechanical and telephone rooms, stairwells, entrances, spaces above
the ceilings and janitorization of said common areas) in which the Sublet Premises are located;

               (f) Utility charges, such as water, gas, electricity, sewer service, waste pick-up and any
other utilities, materials or services furnished directly to the Building in which the Sublet
Premises are located including, without limitation, any temporary or permanent utility surcharge or
other exactions whether or not imposed hereafter;

               (g) Any special assessment levied by the City of Fremont as part of an
improvement district; and

3

 

               (h) Any other charges or expenses that CIPHERGEN is required to pay to Master Lessor
pursuant to the Master Lease, with the exception of charges applicable solely to the portion of
the Building occupied by CIPHERGEN.

               (i) The current annual charges for all items set forth in this Section 3.4 approximates Three
Hundred Seventeen Thousand Dollars ($317,000.00) (allocable to the Sublet Premises), based on the
aggregate amount of such charges and assessments for the Premises in the twelve (12)-month period
prior to the Effective Date hereof;

     The Additional Rent due hereunder shall be paid to Master Lessor for the account of CIPHERGEN,
or, if not acceptable to the Master Lessor to CIPHERGEN, under the Master Lease on or before the
due date, provided CIPHERGEN provides BIO-RAD with adequate notice of the due date of such payment
under the terms of the Master Lease or if there is no such due date pursuant to the Master Lease,
within thirty (30) days after receipt of a reasonably timed invoice therefor.

          3.5 “Fixed Monthly Management Fee”. BIO-RAD shall pay to Master Lessor for the
account of CIPHERGEN, or, if not acceptable to the Master Lessor to CIPHERGEN, a proportionate
share of the fixed monthly management fee charged by Master Lessor to CIPHERGEN pursuant to the
Master Lease, allocated to the Sublet Premises by square footage and payable together with Basic
Rent in accordance with Section 3.3 above, As of the Effective Date hereof such fee is an amount
equal to three percent (3%) of Basic Rent.

     4. Use of Sublet Premises.

          BIO-RAD shall use and occupy the Sublet Premises only for general office, laboratory,
research and development, manufacturing, storage and other uses necessary for BIO-RAD to conduct
BIO-RAD’s business and for no other purpose, provided that such uses shall comply with the Master
Lease and be in accordance with all applicable governmental laws, rules and regulations. CIPHERGEN
reserves the right, on behalf of itself and Master Lessor, upon reasonable notice and at
reasonable times to enter the Sublet Premises to inspect them, to make repairs, to provide
services, to submit the Sublet Premises to prospective purchasers, mortgagers or tenants or to
alter, improve or repair the Sublet Premises or other parts of the Building, all without abatement
of rent; provided, however, that CIPHERGEN shall proceed in good faith and work with Bio-Rad to
not to interfere with the business of BIO-RAD. Notwithstanding the foregoing, CIPHERGEN warrants
that its current use of the Building complies with the Master Lease.

     5. Compliance.

          CIPHERGEN warrants that the improvements to the Sublet Premises comply with all applicable
covenants or restrictions of record and applicable building codes, regulations and ordinances
(“Applicable Requirements”) in effect on the Commencement Date. Such warranty does not apply to any
improvements not placed on the Sublet Premises by CIPHERGEN or to the use to

4

 

which BIO-RAD will put the Sublet Premises beyond its current use or to any approved
alterations or utility installations made or to be made by BIO-RAD. BIO-RAD is responsible for
determining whether or not the zoning for the Sublet Premises is appropriate for any future changes
from its current use.

     6. Acceptance of Premises.

     BIO-RAD acknowledges that: (a) it has made such investigation as it deems necessary of the
condition of the Sublet Premises (including, but not limited to, the electrical, HVAC and fire
sprinkler systems, security, and their suitability for BIO-RAD’s intended use) and accepts the
Sublet Premises “AS IS” and (b) CIPHERGEN has made no representations, promises or warranties
with respect to such matters other than as set forth in this Sublease. BIO-RAD shall not make
any improvements to the Sublet Premises without the prior written consent of CIPHERGEN and
Master Lessor. Notwithstanding the foregoing, BIO-RAD shall not be responsible or have any
liability for any repairs that were required to have been made by CIPHERGEN or by the Master
Lessor under the terms of the Master Lease to the Building or its systems (e.g., HVAC, plumbing,
electrical, etc.) prior to the effective date of this Sublease (but which have not been made).

     7. Alterations and Additions.

          BIO-RAD shall not make, or suffer to be made, any alteration or addition to the Sublet
Premises, or any part thereof, without the written consent of CIPHERGEN and Master Lessor (such
consent not to be unreasonably withheld), but at the cost of BIO-RAD, and any addition to, or
alteration of, the Sublet Premises, except moveable furniture and trade fixtures, shall at once
become a part of the Premises and belong to Master Lessor. BIO-RAD hereby acknowledges that Master
Lessor reserves the right to approve all contractors and mechanics proposed by BIO-RAD to make
such alterations and additions, such approval not to be unreasonably withheld. BIO-RAD shall
retain title to all moveable furniture and trade fixtures placed in the Sublet Premises. All
built-in heating, lighting, electrical air conditioning, permanent floor to ceiling partitioning,
carpeting and permanent floor installations made by BIO-RAD, together with all property that has
become an integral part of the Sublet Premises shall not be deemed trade fixtures. BIO-RAD agrees
that it shall not proceed to make such alterations or additions without having obtained consent
from Master Lessor and CIPHERGEN to do so (such consent by Master Lessor to be given or withheld
in accordance with the Master Lease and such consent by CIPHERGEN not to be unreasonably
withheld), and until five (5) days from the receipt of such consent, in order that CIPHERGEN and
Master Lessor may post reasonable and appropriate notices to, in their judgment, avoid any
liability to contractors or material suppliers for payment for improvements by BIO-RAD. It shall
not be unreasonable for CIPHERGEN to withhold its consent to any alteration or improvement not
consented to by the Master Lessor. BIO-RAD shall at all times permit such notices to be posted and
to remain posted until the completion of work. BIO-RAD shall, if required by Master Lessor, secure
at BIO-RAD’s own cost and expense, a completion and lien indemnity bond, satisfactory to Master
Lessor, for such work. BIO-RAD further covenants and agrees that any legitimate mechanic’s lien
filed against the Building for work claimed to have been done for, or materials claimed to have
been furnished to BIO-RAD, shall be discharged by BIO-RAD, by bond or otherwise, within ten (10)
days after the filing thereof, at the cost and expense of BIO-RAD. Any exceptions to the foregoing
must be made in writing and executed by BIO-RAD, CIPHERGEN and Master Lessor.

5

 

     8. BIO-RAD Maintenance & Surrender.

BIO-RAD shall, at its sole cost and expense, keep and maintain the Sublet Premises (including
appurtenances) and every part thereof in a high standard of maintenance and repair and in good and
sanitary condition and, subject to Section 6, shall perform all maintenance with respect to the
Sublet Premises required of the lessee under the Master Lease. BIO-RAD’s maintenance and repair
responsibilities shall include, without limitation, janitorization, plumbing systems within the
Sublet Premises (such as water and drain lines, and sinks), electrical systems within the
non-common areas of the Sublet Premises (such as outlets, lighting fixtures, lamps, bulbs, tubes,
ballasts), heating and air conditioning controls within the non-common areas of the Sublet
Premises (such as mixing boxes, thermostats, time clocks, supply and return grills), all interior
improvements within the Sublet Premises including, without limitation: wall coverings, window
coverings, acoustical ceilings, vinyl tile, carpeting, partitioning, doors (both interior and
exterior, including closing mechanisms, latches, locks), and all other interior improvements of
any nature whatsoever. BIO-RAD agrees to provide carpet shields under all rolling chairs or to
otherwise be responsible for wear and tear of the carpet caused by such rolling chairs if such
wear and tear exceeds that caused by normal foot traffic in surrounding areas. Areas of such
excessive wear shall be replaced at BIO-RAD’s sole expense upon termination of this Sublease. On
or before the expiration date of the Sublease term, BIO-RAD shall remove all of its personal
property, trade fixtures, and furnishing from the Sublet Premises and surrender possession of the
Sublet Premises to CIPHERGEN in the condition received from CIPHERGEN, except for ordinary wear
and tear not reasonably avoided by performance of the repairs required of BIO-RAD by this
Sublease. If BIO-RAD has made any alterations or improvements to the Sublet Premises, then on or
before the expiration of the Sublease Term, BIO-RAD shall also remove any such alterations and
improvements that Master Lessor requires to be removed and repair all damage caused by such
removal to the reasonable satisfaction of the Master Landlord.

     9. Indemnification and Insurance.

          9.1. Indemnification.

               9.1.1 BIO-RAD shall indemnify, defend and hold CIPHERGEN, Master Lessor and their respective
affiliates, and the officers, directors, employees, servants and agents of each of them, harmless
from and against all claims, demands, damages, losses, costs or other liabilities including,
without limitation, attorney’s fees and costs (a) to the extent caused by the acts or omissions of
BIO-RAD, its employees, servants, agents or contractors in the use or occupation of the Sublet
Premises hereunder or (b) arising out of BIO-RAD’s failure to comply with or perform any obligation
of BIO-RAD hereunder.

               9.1.2 BIO-RAD expressly agrees that neither CIPHERGEN nor Master Lessor shall be liable to
BIO-RAD, and BIO-RAD hereby waives all claims against CIPHERGEN and Master Lessor, for any injury
to or death or any person or damage to or destruction of property in or about the Sublet Premises
by or from any cause whatsoever including, without limitation, gas, fire, oil, electricity or
leakage of any character from the roof, walls, basement or other portion of the Sublet Premises,
except to the extent caused by the negligence of CIPHERGEN or Master

6

 

Lessor or their agents, servants, employees, invitees or contractors of which CIPHERGEN or
Master Lessor, as applicable, has knowledge and reasonable time to correct. Notwithstanding
anything to the contrary in this Sublease, BIO-RAD hereby releases CIPHERGEN and Master Lessor,
their successors and assigns, and the officers, directors, shareholders, employees, agents, and
representatives of CIPHERGEN, Master Lessor, and their successors and assigns, and CIPHERGEN
hereby releases BIO-RAD and Master Lessor, their successors and assigns, and the officers,
directors, shareholders, employees, agents, and representatives of BIO-RAD and Master Lessor, and
their successors and assigns, and Master Lessor by execution of its consent to this Sublease
releases CIPHERGEN and BIO-RAD, their

successors and assigns, and the officers, directors, shareholders, employees, agents, and
representatives of CIPHERGEN, BIO-RAD, and their successors and assigns, from all liability,
loss, damage, cost, and expense caused by fire or any of the extended coverage casualties
included in the releasing party’s insurance policies, irrespective of the cause of such fire or
casualty; provided, however, that if the insurance policy of either releasing party prohibits
such waiver then this waiver shall not take effect until consent to such waiver is obtained. If
such waiver is prohibited, the insured party affected shall promptly notify the other party
thereof.

          9.1.3 CIPHERGEN shall indemnify, defend and hold BIO-RAD and its affiliates, and the
officers, directors, employees, servants and agents of each of them, harmless from and against
all claims, demands, damages, losses, costs or other liabilities including, without limitation,
attorney’s fees and costs (a) to the extent caused by the acts or omissions of CIPHERGEN, its
employees, servants, agents or contractors in the use or occupation of the Premises hereunder,
including any default of its obligations under the Master Lease, or (b) arising out of
CIPHERGEN’s failure to comply with or perform any obligation of CIPHERGEN hereunder.

          9.2 Insurance.

               9.2.1 BIO-RAD, at BIO-RAD’s expense, agrees to keep in force during the term of this
Sublease all of the insurance required of the lessee under Section 12 of the Master Lease and,
at a minimum, also shall keep in force during the term of this Sublease a policy of commercial
general liability insurance with combined single limit coverage of not less than $2,000,000 per
occurrence for bodily injury and property damage occurring in, on or about the Sublet Premises,
including parking and landscaped areas. Such insurance shall be primary and
noncontributory as respects any insurance carried by CIPHERGEN or Master Lessor. The policy
or policies effecting such insurance shall (a) name CIPHERGEN and Master Lessor as additional
insureds, and shall insure any liability of CIPHERGEN and Master Lessor, contingent or otherwise,
as respects acts or omissions of BIO-RAD, its agents, employees or invitees or otherwise by any
conduct or transactions of any of such persons in or about or concerning the Sublet Premises,
including any failure of BIO-RAD to observe or perform any of its obligations hereunder, (b) be
issued by an insurance company licensed in the State of California with a Best rating of not less
than AM Best rating of A-, VII or better and (c) BIO-RAD shall endeavor to provide thirty (30)
days prior written notice to CIPHERGEN prior to any cancellation of such policy. BIO-RAD shall
deliver a certificate of insurance to CIPHERGEN upon request substantiating such insurance
coverage upon execution of this Sublease.

7

 

               9.2.2 BIO-RAD shall maintain a policy or policies of fire and property damage insurance in
“all risk” form with a sprinkler leakage endorsement insuring the personal property, inventory
and trade fixtures within the Sublet Premises for the full replacement value thereof. BIO-RAD
shall also maintain a policy or policies of worker’s compensation insurance and any other
employee benefit insurance sufficient to comply with all applicable laws.

     10. Confidential Information.

          10.1 Procedures to Protect Confidential Information. CIPHERGEN and BIORAD shall
engage in a good faith effort to develop mutually agreed upon written procedures for protecting
each party’s respective Confidential Information (as that term is defined in the Confidentiality
Agreement effective August 14, 2006 between the parties). Each party shall (a)
ensure that each of its employees, servants, agents or contractors performing work or services for
such party in the Building is fully informed of the existence and content of such procedures and
(b) include in each such employee’s, servant’s, agent’s or contractor’s personnel or contract file
a written statement signed by such Representative that he or she (i) has read and understands and
(ii) agrees to comply with such procedures.

     11. Miscellaneous.

          11.1 Assignment and Subletting. BIO-RAD shall not assign, transfer or hypothecate the
leasehold estate under this Sublease or any interest therein and shall not sublet the Sublet
Premises or any part thereof, or permit any person or entity unrelated to BIO-RAD to occupy or use
the Sublet Premises or any portion thereof, without the express prior written consent of CIPHERGEN
and Master Lessor, such consent by CIPHERGEN not to be unreasonably withheld and such consent by
the Master Lessor to be given or withheld in accordance with the Master Lease. Notwithstanding the
foregoing, CIPHERGEN agrees that BIO-BAD may assign this Sublease to a successor company of the
business occupying the Sublet Premises without the consent of CIPHERGEN, provided BIO-RAD obtains
all consents to such assignment from the Master Lessor as required by the Master Lease.

          11.2 Notices. All notices, requests, demands, consents and other communications which
are required or may be given under this Sublease shall be in writing and shall be deemed to have
been duly given when received if personally delivered; when transmitted if transmitted by
facsimile, electronic or digital transmission method; the day after it is sent, if sent for next
day delivery to a domestic address by recognized overnight delivery service (e.g., Federal
Express) and upon receipt, if sent by certified or registered mail, return receipt requested. In
each case, notice shall be sent to:

If to CIPHERGEN, to:

Ciphergen Biosystems, Inc.

6611 Dumbarton Circle

Fremont, California 94555

Attn: Facilities Manager

Telephone: (510) 505-2100

Facsimile: (510) 505-2101

8

 

If to BIO-RAD, to:

Bio-Rad Laboratories, Inc.

1000 Alfred Nobel Drive

Hercules, CA 94547

Attn: General Counsel

Telephone: (510) 741-1000

Facsimile: (510) 741-5815

If to Master Lessor, to:

Peery/Arrillaga

2560 Mission College Blvd.

Suite 101

Santa Clara, CA 95054

or to such other place and with such other copies as either party may designate as to itself
by written notice to the other party.

          11.3 Choice of Law/Dispute Resolution

               (a) Choice of Law. This Sublease shall be construed, interpreted and the rights of
the parties determined in accordance with the laws of the State of California (without reference
to the choice of law provisions), except with respect to matters of law concerning the internal
corporate affairs of any corporate entity which is a party to or the subject of this Sublease.

               (b) Dispute Resolution. The parties shall attempt to resolve informally, through their
respective representatives on the Joint Steering Committee (as such term is defined in the Asset
Purchase Agreement of even date herewith between the parties), any dispute, claim or controversy
(“Dispute”) arising between the parties with respect to the performance of this Sublease.
If the Joint Steering Committee is unable to resolve any such Dispute within sixty (60) days, the
party raising the Dispute shall promptly advise the other party in a writing (“Notice of
Dispute”) of its desire to submit the Dispute to an alternative dispute resolution (“ADR)
process. The Notice of Dispute shall describe the nature of the Dispute in reasonable detail. By
not later than ten (10) business days after the recipient has received such Notice of Dispute, each
party shall have selected for itself a representative who shall have the authority to bind each
such party and shall additionally have advised the other party in writing of the name and title of
such representative. By not later than twenty (20) business days after the date of such Notice of
Dispute, such representatives shall schedule a date for engaging in an ADR process. Thereafter, the
representatives of the parties shall engage in good faith in an ADR process. If the representatives
of the parties have not been able to resolve the Dispute within thirty (30) business days after the
termination of the ADR, the parties shall have the right to pursue any other remedies legally
available to resolve such dispute in either the State Courts of California or in the United States
District Courts for California. Each party irrevocably and unconditionally (1) agrees
that any ADR process, suit, action or other legal proceeding arising out of this Sublease may be
brought in the United States District Court for the Northern District of California or, if such
court does not have jurisdiction or will not accept jurisdiction, in any court of general
jurisdiction in Contra Costa County, California, (2) consents to the Jurisdiction or any such court
in any such suit, action or proceeding, and (3) waives any

9

 

objection which such party may have to the laying of venue of any such suit, action or
proceeding in any such court. Notwithstanding the foregoing, nothing in this Section 11.3 (b) shall
be construed to waive any rights or timely performance of any obligations existing under this
Sublease. Notwithstanding anything to the contrary in this Section, the procedures set forth above
shall not govern any dispute to which the Master Lessor is a party, unless and until the Master
Lessor agrees to be bound by the foregoing with respect to such dispute.

          11.4 Entire Agreement; Amendments and Waivers. BlO-RAD acknowledges that this
Sublease is subject to the terms and conditions of the Master Lease, the terms of which are
hereby incorporated into this Sublease, subject to the following:

(i) each reference in such incorporated sections to “Lease” shall be deemed a
reference to “Sublease”;

(ii) each reference to the “Premises" shall be deemed a
reference to the “Sublet Premises” herein subleased;

(iii) each reference to “Landlord” and “Tenant” shall be deemed a reference to
“Sublessor” and “Sublessee", respectively, except as otherwise expressly
set forth herein;

(vi) with respect to any approval required to be obtained from the “Landlord” under
the Master Lease, such consent must be obtained from both Master Lessor and
Sublessor, and the approval of Sublessor may be withheld if Master
Lessor‘s consent is not obtained;

(vii) in any case where “Tenant” is to execute and deliver certain documents or
notices to “Landlord”, such obligation shall be deemed to run from Sublessee to
both Master Lessor and Sublessor;

(ix) subject to the foregoing, the following provisions of the Master Lease shall
not be incorporated herein: Preamble (parties), Section 2 (term), Section 4.A
(rent amount), Section 4.0 (late charge), Section 4.F (place for rent payment),
Section 4.G (security deposit), Section 31 (notices), Section 39 (rent amount),
First Amendment Section 2 (state of incorporation change), First Amendment Section
6 (rent amount), First Amendment Section 7 (security deposit), First Amendment
Section 8 (parking), First Amendment Section 9 (tenant maintenance), First
Amendment Section 11 (utilities), and such other provisions that conflict or are
inconsistent with this Sublease, or are not reasonably applicable to Sublessee.

In the event of any conflict or inconsistency between the provisions of this Sublease and the
Master Lease, the Master Lease shall control as between the parties and the Master Lessor and
this Sublease shall control as between the parties hereto. The Master Lease is attached hereto
as Schedule B. This Sublease, together with together with all exhibits hereto, and the
Confidentiality Agreement, constitutes the entire agreement between the parties pertaining to
the subject matter hereof and supersedes all prior agreements, understandings, negotiations and
discussions, whether oral or written, of the parties. This Sublease may not be amended except by
an instrument in

10

 

writing signed on behalf of each of the parties hereto. No amendment, supplement modification or
waiver of this Sublease shall be binding unless executed in writing by the party to be bound
thereby. No waiver of any of the provisions of this Sublease shall be deemed or shall constitute
a waiver of any other provision hereof (whether or not similar), nor shall such waiver
constitute a continuing waiver unless otherwise expressly provided,

          11.5 Multiple Counterparts. This Sublease may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.

          11.6 Invalidity. In the event that any one or more of the provisions contained in
this Sublease or in any other instrument referred to herein, shall, for any reason, be held to be
invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by law,
such invalidity, illegality or unenforceability shall not affect any other provision of this
Sublease or any other such instrument.

          11.7 Attorney’s Fees. If any party to this Sublease brings an action to enforce its
rights under this Sublease, the prevailing party shall be entitled to recover its costs and
expenses including, without limitation, reasonable attorney’s fees, incurred in connection with
such action, including any appeal of such action.

          11.8 Independent Contractors. CIPHERGEN and BIO-RAD, and their respective agents,
shall be independent contractors with respect to the transactions contemplated herein and nothing
herein shall be deemed to constitute a relationship of partnership, joint venture,
employee-employer or any other relationship other than that of independent contracting parties.
Neither party, nor its agents shall hold itself out to third parties as having the power to
contractually bind the other party with respect to any matter.

          11.9 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY, ITS SUBSIDIARIES OR
AFFILIATES BE LIABLE TO THE OTHER PARTY, ITS SUBSIDIARIES OR AFFILIATES, FOR ANY SPECIAL,
CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER CAUSED AND ON
ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS SUBLEASE, WHETHER
OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

          11.10 Force Majeure. Neither party shall be responsible for any delay or failure in
performance (or for any loss, damage, cost, charge or expense incurred or suffered by the other
party by reason of such delay or failure) if that delay or failure is a result of an event beyond
the reasonable control of that party, and without the fault or negligence of that party;

          11.11. Master Lessor Consent. BIO-RAD acknowledges that execution of this Sublease is
conditioned on the prior consent of Master Lessor.

[Signature page follows]

11

 

IN WITNESS WHEREOF, CIPHERGEN and BIO-RAD have caused this Sublease to be executed by their
authorized representatives.

	 	 	 	 	 	 	 	 	 	 	 
	CIPHERGEN BIOSYSTEMS, INC.	 	 	 	BIO-RAD LABORATORIES, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Debra Young
	 	 	 	By:
	 	/s/ Sanford Wadler	 	 
	Name:

	 	 

Debra Young
	 	 	 	Name:
	 	 

Sanford Wadler
	 	 
	Its:

	 	CFO and VP of Finance
	 	 	 	Its:
	 	Vice President & General Counsel	 	 

 

SCHEDULE A

FACILITY SCHEDULE AND MAP

	 	 	 	 	 
	BIO-RAD area	 	Sq.ft
	Consumables manufacturing
	 	 	4,100	 
	Consumables handling/QC/storage
	 	 	3,136	 
	Instrument manufacturing
	 	 	5,770	 
	Instrument handling/QC/storage
	 	 	896	 
	Chip Applications/Service lab
	 	 	1,760	 
	Office space
	 	 	7,500	 
	Field Service lab/inventory
	 	 	908	 
	Utilities
	 	 	931	 
	Corridors
	 	 	1,152	 
	total
	 	 	26,153	 

	 	 	 	 	 
	Shared areas	 	 	 	 
	Restrooms (half)
	 	 	832	 
	lunch room (half)
	 	 	576	 
	Lobby (none)
	 	 	—	 
	Shipping/Receiving (70%)
	 	 	1,434	 
	total
	 	 	2,842	 
	 
	Total subleased area
	 	 	28,995	 

13

 

SCHEDULE B

MASTER LEASE

14

 

SCHEDULE C

WIRE TRANSFER INSTRUCTIONS

[**************************]

[**************************]

[**************************]

	 	 	 
	Bank account #:

	 	[*********************]
	ABA Routing #:

	 	[*********************]
	Account Name:

	 	[*********************]
	Swift Code:

	 	[*********************]

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. Omitted portions have been filed separately with the
Commission.***

15exv10w61

 

Exhibit 10.61

CONFIDENTIAL

Placement Agent Agreement

March 28, 2007

Oppenheimer & Co. Inc.

125 Broad Street

New York, NY 10004

Dear Gail:

     The undersigned Ciphergen Biosystems, Inc., a Delaware corporation (the “Company”), hereby
agrees (the “Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer” or the “Placement Agent”) as
follows:

     1. Best Efforts Offering. The Company hereby engages Oppenheimer to act as its
exclusive placement agent during the term of the offering as outlined herein to sell up to $25
million of Common Stock and Warrants (the “Securities”), on a “best efforts” basis (the
“Offering”). It is understood that in the event potential investors are concerned that the SEC’s
recent interpretation of Rule 415 could impact the Company’s ability to have the securities
registered in a timely manner, then the Offering may be limited to 35% of the Company’s public
float. Oppenheimer intends to initially market the Offering on the terms as set forth in the Term
Sheet attached hereto as Exhibit A. However, the ultimate terms will depend upon various
factors including, but not limited to, the overall market conditions at that time, the interest of
potential investors and the Company’s capitalization. The Securities shall be offered without
registration under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the “Act”) pursuant to the exemption from registration created by
Regulation D thereof.

     2. Offering Materials. The Company shall, as soon as practicable, prepare a public
offering package (the “Offering Materials”), which shall meet the anti-fraud and other requirements
of the federal and state securities laws, be in form and substance reasonably satisfactory to the
parties and will include the Company’s public documents and any other appropriate updated
information.

     3. Compensation.

     (a) Oppenheimer will be paid at closing of the Offering a cash commission of 6.0% of the
aggregate amount of the proceeds received by the Company at closing for the Securities sold. In
addition, Oppenheimer shall receive non-callable warrants (but shall be subject to earlier
termination in the event of an acquisition of the Company in which the Company’s stockholders
receive cash consideration for their shares of Company stock) with a five (5) year term to purchase
that number of shares of the Company’s Common Stock equal to 4.0% of the number of shares of common
stock sold in the Offering, exercisable at 120% of the Market Price at closing of the Offering (the
“Placement Warrants”). The Placement Warrants shall provide for cashless net exercise. In
addition, if Quest Diagnostics, Incorporated invests in the Offering, then Oppenheimer shall be
paid only 75% of the amount entitled to hereunder and if any officers or directors of the Company
invests in the Offering, then Oppenheimer shall be paid only 50% of the amount entitled to
hereunder.

     (b) Notwithstanding anything to the contrary herein, if, during the term of the Offering
hereunder, a potential investor, other than Quest Diagnostics, Incorporated or any officers or
directors of the Company, is informed of the Offering, and if (i) the Offering hereunder does not
close and such investor purchases any private securities of the Company within 12 months after the

 

 

termination of the Offering, or (ii) the Offering hereunder closes and such investor makes an
investment in the Offering and subsequently purchases within 12 months after the closing of the
Offering any private securities of the Company, then Oppenheimer shall be entitled to its
compensation as set forth in paragraph 3(a) above.

     4. Expenses. Whether or not the Offering is successfully completed, it shall be the
Company’s obligation to bear all of its expenses in connection with the proposed Offering,
including Blue Sky legal fees and expenses, if any. In addition, the Company shall reimburse
Oppenheimer for its out-of-pocket expenses, including reasonable legal fees and disbursements not
to exceed $40,000, of which $25,000 is payable to Oppenheimer upon execution of this agreement.

     5. Further Representations and Agreements 

     (a) In addition to the terms and conditions in Exhibit A, the Company further represents and
agrees that (i) it is authorized to enter into this Agreement and to carry out the Offering
contemplated hereunder and that this Agreement constitutes a legal, valid, and binding obligation
of the Company, enforceable in accordance with its terms; (ii) the Company shall not issue any
additional shares (other than shares pursuant to the exercise of warrants), options (other than
pursuant to its existing stock option plan or successor plan covering no more securities than the
existing plan), or warrants during the term of the Offering; and (iii) the Company will, during the
course of the Offering, provide Oppenheimer with all information and copies of documentation with
respect to the Company’s business, financial condition, and other matters as Oppenheimer may
reasonably deem relevant, including copies of all documents sent to stockholders or filed with any
federal authorities, and will make reasonably available to Oppenheimer, its auditors, counsel, and
officers and directors to discuss with Oppenheimer any aspect of the Company or its business which
Oppenheimer may reasonably deem relevant.

     6. Indemnification. — See Exhibit B attached hereto, and incorporated herein
by reference.

     7. No-Shop Provision. Until the Offering contemplated hereby is closed or terminated,
the Company agrees that it will not negotiate with any other person relating to a possible public
or private offering or placement of the Company’s securities. In addition, if there is no Closing
or completed Offering as set forth herein and the Company enters into discussions to merge or sell
the Company with any third party, then the Company shall explore in good faith retaining
Oppenheimer as its mergers and acquisition advisor for such transaction (pursuant to a separate
agreement) on terms and conditions mutually acceptable to the Company and Oppenheimer.
Notwithstanding the foregoing, the Company is under no obligation to retain Oppenheimer as its
mergers and acquisitions advisor and may elect not to do so in its sole discretion.

     8. Termination. The Company shall have the right to terminate the Offering in the
event it is not completed within 45 days from the launch date of the roadshow. The Company and
Oppenheimer may terminate or extend the Agreement at any time by mutual written consent.

     9. Competing Claims. The Company acknowledges and agrees that no entity has any
claims or is entitled to any payments for services in the nature of a finder’s fee or any other
arrangements, agreements, payments or understandings pursuant to this Offering.

     10. Miscellaneous.

     (a) Governing Law. This Agreement and the transactions contemplated hereby shall be
governed in all respects by the laws of the State of New York, without giving effect to its
conflict of laws principles.

 

 

     (b) Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original and all of which together shall constitute one and the same
instrument.

     (c) Notices. Whenever notice is required to be given pursuant to this Agreement,
such notice shall be in writing and shall either be (i) mailed by certified first class mail,
postage prepaid, addressed (a) if to Oppenheimer, at the address set forth at the head of this
Agreement, Attention: Kee Colen, Managing Director; and (b) if to the Company, at Ciphergen
Biosystems, Inc., Attention: Gail S. Page, President and CEO; or (ii) delivered personally or by
express courier. The notice shall be deemed given, if sent by mail, on the third day after deposit
in a United States post office receptacle, or if delivered personally or by express courier, then
upon receipt.

     (d) Dispute. In the event of any action at law, suit in equity or arbitration
proceeding in relation to this Agreement or the transactions contemplated by this Agreement, the
prevailing party, or parties, shall be paid its reasonable attorney’s fees and expenses arising
from such action, suit, or proceeding by the other party.

     If the foregoing correctly sets forth the understanding between Oppenheimer and the Company,
please so indicate in the space provided below for that purpose whereupon this letter shall
constitute a binding agreement between us.

	 	 	 	 	 
	 	Sincerely,

Ciphergen Biosystems, Inc.

 	 
	 	By:  	/s/ Gail S. Page
 	 
	 	 	Gail S. Page 	 
	 	 	President and CEO 	 
	 

	 	 	 	 	 
	Confirmed and agreed to:

Oppenheimer & Co. Inc.

 	 
	By:  	/s/ Kee Colen
 	 
	 	Kee Colen 	 
	 	Managing Director 	 
	 

Date: 3/28/2007

 

 

Exhibit A

Ciphergen Biosystems, Inc.

Private Placement of Common Stock with Warrants —

Preliminary Term Sheet

	 	 	 
	 
	 	 
	Issue:

	 	Up to $25 million of common stock (the “Common Stock”) and Warrants (as defined below) (the “Securities”)
issued to accredited investors only pursuant to Regulation D (the “Offering”).
	 
	 	 
	Issue Price:

	 	At the Market Price as defined by NASDAQ so that the Company complies with listing requirements for an “at
market” deal. The Pricing Date is defined as the date in which the Securities Purchase Agreement (“SPA”)
is entered into by the investors and accepted by the Company.
	 
	 	 
	Warrants:

	 	The amount of warrants shall be determined based on investor demand and market conditions. The life of
the warrants shall be 5 years with an exercise price at a premium to the Market Price. To qualify as an
“at market” deal, the investor will need to pay $0.125 per warrant.
	 
	 	 
	Registration Rights:

	 	The Company shall use its best efforts to file with the SEC a registration statement (the “Registration
Statement”) for the Securities within 30 days of the Pricing Date and to have such Registration Statement
declared effective within 90 days of the Pricing Date; if the Company does not have the Registration
Statement filed within 30 days of the Pricing Date or declared effective within 90 days of the Pricing
Date, the Company shall pay the investors a cash penalty on a monthly basis of 1.5% of the value of their
investment for as long as the Registration Statement is not effective. If the SEC reviews the Registration
Statement, then the effectiveness clause shall be increased to 120 days.
	 
	 	 
	Lock Up:

	 	All executive officers, directors and affiliates of the Company shall enter into a lock up agreement with
Oppenheimer in which they will agree not to sell any shares held by them under Rule 144 or otherwise for a
period from the date hereof until the later of six (6) months from the closing hereunder or 90 days
following the effective date of a Registration Statement in which the Securities are included. The Company
agrees that for a period of 90 days after the effectiveness of the Registration Statement, it shall not
issue or sell any equity linked securities of the Company, unless the issuance or sale is related to a
strategic transaction or an employee, consultant, supplier, lender, lessor or option grant or issuance.
	 
	 	 
	Use of Proceeds:

	 	Product development, R&D spending and general corporate purposes.
	 
	 	 
	Purchase Agreement:

	 	The Common Stock and Warrants shall be purchased pursuant to the SPA which shall contain representations,
warranties and covenants of the Company and conditions to closing customary for a transaction of this
kind.
	 
	 	 
	Closing:

	 	The financial closing shall occur within three business days following the Pricing Date (the “Closing
Date”).
	 
	 	 
	Other:

	 	The Company further represents and agrees that it will deliver at the closing of the Offering (a) a
certificate of each of the Company’s CEO and CFO to the effect that the offering materials meets the
requirements hereof and does not contain any untrue statement of material fact or fail

 

 

	 	 	 
	 

	 	to state any material fact required to be stated therein or necessary
to make the statements therein not misleading and all necessary
corporate approvals have been obtained to enable the Company to
deliver the Securities in accordance with the terms of the Offering,
and (b) an opinion of counsel for the Company in customary form.

 

 

			
	EXHIBIT B
	 	March 28, 2007

Oppenheimer & Co. Inc.

125 Broad Street

New York, New York 10004

Attention:

Kee Colen

Managing Director

Dear Mr. Colen:

In connection with our engagement of Oppenheimer & Co. Inc. (“Oppenheimer”) as our exclusive
placement agent, we hereby agree to indemnify and hold harmless Oppenheimer and its affiliates, and
the respective controlling persons, directors, officers, shareholders, agents and employees of any
of the foregoing (collectively the “Indemnified Persons”), from and against any and all claims,
actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses
incurred by any of them (including the reasonable fees and expenses of counsel), (collectively a
“Claim”), which are (A) related to or arise out of (i) any actions taken or omitted to be taken
(including any untrue statements made or any statements omitted to be made) by the Company, or (ii)
any actions taken or omitted to be taken by any Indemnified Person in connection with our
engagement of Oppenheimer, or (B) otherwise relate to or arise out of Oppenheimer’s activities on
our behalf under Oppenheimer’s engagement, and we shall reimburse any Indemnified Person for all
expenses (including the reasonable fees and expenses of counsel) incurred by such Indemnified
Person in connection with investigating, preparing or defending any such claim, action, suit or
proceeding, whether or not in connection with pending or threatened litigation in which any
Indemnified Person is a party. We will not, however, be responsible for any Claim, which is
finally judicially determined to have resulted from the gross negligence or willful misconduct of
any person seeking indemnification hereunder. We further agree that no Indemnified Person shall
have any liability to us for or in connection with our engagement of Oppenheimer except for any
Claim incurred by us as a result of any Indemnified Person’s gross negligence or willful
misconduct.

We further agree that we will not, without the prior written consent of Oppenheimer, settle,
compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of
which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual
or potential party to such Claim), unless such settlement, compromise or consent includes an
unconditional, irrevocable release of each Indemnified Person hereunder from any and all liability
arising out of such Claim.

Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or
institution of any Claim with respect to which indemnification is being sought hereunder, such
Indemnified Person shall notify us in writing of such complaint or of such assertion or institution
but failure to so notify us shall not relieve us from any obligation we may have hereunder, unless
and only to the extent such failure results in the forfeiture by us of substantial rights and
defenses. If we so elect or are requested by such Indemnified Person, we will assume the defense
of such Claim, including the employment of counsel reasonably satisfactory to such Indemnified
Person and the payment of the fees and expenses of such counsel. In the event, however, that legal
counsel to such Indemnified Person reasonably determines and

 

 

provides written correspondence to us, that having common counsel would present such counsel with a
conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified
Person and us, and legal counsel to such Indemnified Person reasonably concludes that there may be
legal defenses available to it or other Indemnified Persons different from or in addition to those
available to us, then such Indemnified Person may employ its own separate counsel to represent or
defend it in any such Claim and we shall pay the reasonable fees and expenses of such counsel.
Notwithstanding anything herein to the contrary, if we fail timely or diligently to defend,
contest, or otherwise protect against any Claim, the relevant Indemnified Party shall have the
right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or
counterclaims or otherwise protect against the same, and shall be fully indemnified by us therefor,
including without limitation, for the reasonable fees and expenses of its counsel and all amounts
paid as a result of such Claim or the compromise or settlement thereof. In any Claim in which we
assume the defense, the Indemnified Person shall have the right to participate in such Claim and to
retain its own counsel therefor at its own expense.

We agree that if any indemnity sought by an Indemnified Person hereunder is unavailable for any
reason then (whether or not Oppenheimer is the Indemnified Person), we and Oppenheimer shall
contribute to the Claim for which such indemnity is held unavailable in such proportion as is
appropriate to reflect the relative benefits to us, on the one hand, and Oppenheimer on the other,
in connection with Oppenheimer’s engagement referred to above, subject to the limitation that in no
event shall the amount of Oppenheimer’s contribution to such Claim exceed the amount of fees
actually received by Oppenheimer from us pursuant to Oppenheimer’s engagement. We hereby agree
that the relative benefits to us, on the one hand, and Oppenheimer on the other, with respect to
Oppenheimer’s engagement shall be deemed to be in the same proportion as (a) the total value paid
or proposed to be paid or received by us or our stockholders as the case may be, pursuant to the
transaction (whether or not consummated) for which you are engaged to render services bears to (b)
the fee paid or proposed to be paid to Oppenheimer in connection with such engagement.

Our indemnity, reimbursement and contribution obligations under this Agreement shall be in addition
to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Party
may have at law or at equity.

The validity and interpretation of this agreement shall be governed by and construed and enforced
in accordance with the laws of the State of New York applicable to agreements made and to be fully
performed therein (excluding the conflicts of laws rules). Each of Oppenheimer and the Company
hereby irrevocably submits to the jurisdiction of any court of the State of New York, County of New
York or the United States District Court for the Southern District of New York for the purpose of
any suit, action or other proceeding arising out of this agreement or the transactions contemplated
hereby, which is brought by or against Oppenheimer or the Company and in connection therewith, each
of Oppenheimer and the Company (i) hereby irrevocably agrees that all claims in respect of any such
suit, action or proceeding may be heard and determined in any such court, (ii) to the extent that
it has acquired, or hereafter may acquire, any immunity from jurisdiction of any such court or from
any legal process therein, it hereby waives, to the fullest extent permitted by law, such immunity
and (iii) agrees not to commence any action, suit or proceeding relating to this agreement other
than in any such court. Each of Oppenheimer and the Company hereby waives and agrees not to assert
in any such action, suit or proceeding, to the fullest extent permitted by applicable law, any
claim that (a) it is not personally subject to the jurisdiction of any such court, (b) it is immune
from any legal process (whether through service or notice, attachment prior to judgment, attachment
in aid of execution, execution or otherwise) with respect to its property of (c) any suit, action
or proceeding is brought in an inconvenient forum.

 

 

The provisions of this Agreement shall remain in full force and effect following the completion or
termination of Oppenheimer’s engagement.

	 	 	 	 	 
	 	Sincerely,

Ciphergen Biosystems, Inc.

 	 
	 	By:  	 	 
	 	 	Gail S. Page 	 
	 	 	President and CEO 	 
	 

	 	 	 	 	 
	Confirmed and agreed to:

Oppenheimer & Co. Inc.

 	 
	By:  	 	 
	 	Kee Colen 	 
	 	Managing Director
 	 
	 	
 	 
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]